Synlife has generated multiple formulations of synthetic cells for different indications.
SOBER, Synlife’s lead formulation, is targeted at removal of ethanol from the blood of alcohol poisoning patients. Current standards of care can address symptoms but not the underlying cause of alcohol poisoning. This results in patients lingering at dangerous levels of blood alcohol for many hours and a long recovery period. SOBER is being engineered to enable rapid removal of ethanol from the blood with the end goal of saving the lives and expediting recovery of acutely poisoned patients.
Synlife’s second formulation is being developed as a combination therapy of Synthetic Cells containing purine nucleoside phosphorylase (PNP) and cytosine deaminase (CD) and the chemotherapeutic drug precursors fludarabine and 5-fluorocytosine. The Synthetic Cells will be targeted to solid tumors, where they will facilitate conversion of fludarabine and 5-fluorocytosine into their active forms. This concentrates the chemotherapeutic drugs at the site of the tumor and allows for much more potent tumor cell killing.
